Surrozen (SRZN) Operating Expenses (2020 - 2026)
Surrozen (SRZN) posted quarterly Operating Expenses of $15.5 million for Q1 2026, up 46.72% year-over-year from $10.5 million in Q1 2025, and up 17.38% quarter-over-quarter from $13.2 million in Q4 2025.
Surrozen (SRZN) Operating Expenses (2020 - 2026) Analysis & Trends
Surrozen's Operating Expenses history runs 7 years deep, the most recent figure standing at $15.5 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 46.72% year-over-year to $15.5 million; the TTM figure through Mar 2026 stood at $50.5 million (up 34.29% YoY), while the FY2025 annual figure was $45.6 million, up 25.9% from the prior year.
- Operating Expenses for Q1 2026 stood at $15.5 million, up from $13.2 million in the prior quarter.
- The five-year high for Operating Expenses was $15.5 million in Q1 2026, with the low at $8.8 million in Q3 2024.
- The 5-year median for Operating Expenses is $11.2 million (2023), against an average of $11.8 million.
- The sharpest annual moves came in 2024 and 2026: Operating Expenses slumped 37.43% in 2024, then soared 46.72% in 2026.
- Surrozen's Operating Expenses stood at $14.7 million in 2022, then slumped by 33.71% to $9.7 million in 2023, then declined by 4.91% to $9.2 million in 2024, then jumped by 42.39% to $13.2 million in 2025, then rose by 17.38% to $15.5 million in 2026.
- Business Quant data shows SRZN's Operating Expenses at $15.5 million in Q1 2026, $13.2 million in Q4 2025, and $11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 15.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.37 Mn |
| Mar 31, 2026 | 15.46 Mn |
| Dec 31, 2025 | 13.17 Mn |
| Sep 30, 2025 | 11.87 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 10.53 Mn |
| Dec 31, 2024 | 9.25 Mn |
| Sep 30, 2024 | 8.77 Mn |
| Jun 30, 2024 | 9.05 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 9.72 Mn |
| Sep 30, 2023 | 11.19 Mn |
| Jun 30, 2023 | 10.28 Mn |
| Mar 31, 2023 | 14.59 Mn |
| Dec 31, 2022 | 14.67 Mn |
| Sep 30, 2022 | 13.61 Mn |
| Jun 30, 2022 | 14.07 Mn |
| Mar 31, 2022 | 14.49 Mn |
| Dec 31, 2021 | 15.00 Mn |
| Sep 30, 2021 | 13.71 Mn |